Tesamorelin Online Buyer's Guide: Egrifta vs Compounded, Pricing, and How to Get a Prescription in 2026

Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC. Last reviewed May 27, 2026.

The short answer

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to release more of the body's own growth hormone in a natural pulsatile pattern. It is FDA-approved as Egrifta for HIV-associated abdominal lipodystrophy and prescribed off-label for visceral fat reduction, age-related growth hormone optimization, and body composition goals.

Branded Egrifta runs approximately $2,000 to $3,500 per month at standard dosing. The same active molecule compounded by a 503A pharmacy runs $100 to $200 per vial under a prescription. For cash-pay patients (most non-HIV indications) compounded tesamorelin is the practical choice. RxPepsDirect prescribes tesamorelin at 15mg, tesamorelin high-dose at 24mg, and the tesamorelin/ipamorelin blend via Optimal Balance Pharmacy, with a $39 medical visit fee that covers up to three peptides per order.

What tesamorelin actually is

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, the hypothalamic peptide that signals the pituitary gland to release growth hormone. The molecule is a stabilized 44-amino-acid peptide engineered for greater stability and longer half-life than native GHRH while preserving the receptor binding activity.

When tesamorelin binds GHRH receptors on the anterior pituitary, it triggers the release of stored growth hormone into circulation in a natural pulsatile pattern. The body's own feedback mechanisms remain intact, so growth hormone release stays regulated rather than crossing into supraphysiological excess. This is the mechanistic argument for GHRH analogs over recombinant human growth hormone (HGH): GHRH analogs amplify the body's own production within natural feedback control, while recombinant HGH bypasses feedback entirely.

Tesamorelin received FDA approval in 2010 as Egrifta (tesamorelin for injection) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The approval was based on phase III trials showing meaningful visceral adipose tissue reduction in the HIV lipodystrophy population. The same mechanism that reduces visceral fat in HIV patients works in non-HIV patients with elevated visceral adiposity, which drives the off-label use.

Egrifta vs compounded tesamorelin

The compounded versus branded question is the most common point of confusion for patients new to tesamorelin. The biochemistry is the same; the regulatory frame, formulation specifics, and price differ significantly.

Egrifta is the branded FDA-approved product manufactured by Theratechnologies. It is supplied as a powder plus diluent in a specific vial size with a specific reconstitution and dosing protocol. Egrifta has indication- specific FDA approval (HIV-associated abdominal lipodystrophy) and a published clinical trial evidence base supporting the approval. Retail pricing in the United States runs approximately $2,000 to $3,500 per month at the FDA-approved 2mg daily dose, depending on pharmacy and insurance.

Compounded tesamorelin is the same active pharmaceutical ingredient (tesamorelin acetate) prepared by a 503A compounding pharmacy under Section 503A of the Federal Food, Drug, and Cosmetic Act. The compounded product is dispensed under a patient-specific prescription written by a licensed clinician documenting the indication. Compounded tesamorelin is not FDA-approved as a drug product (compounded medications generally are not), but it is legally dispensable under the 503A pathway.

The clinical question for the patient: does compounded tesamorelin produce the same effect as Egrifta? The active molecule is the same, the receptor binding is the same, and the biological response is the same when dose and route match. Differences are in formulation (vial size, stabilizers, reconstitution protocol) rather than in mechanism. For the off-label indications most patients seek (visceral fat reduction, GH optimization), the clinical observation base supports the same outcomes with compounded versus branded.

The economic question for the patient: insurance generally does not cover Egrifta for non-HIV indications (the off-label uses that drive most patient interest). At cash-pay prices, $2,000+ per month for branded versus $100 to $200 per vial for compounded is a meaningful difference. Most non-HIV patients choose compounded.

Tesamorelin for visceral fat reduction

The strongest clinical evidence for tesamorelin is in visceral fat reduction. The Egrifta phase III trials in HIV patients with lipodystrophy showed average visceral adipose tissue (VAT) reduction of 15 to 18 percent over 26 weeks at the FDA-approved 2mg daily dose. The reduction is selective for visceral fat (the metabolically active fat that wraps around abdominal organs); subcutaneous fat is not preferentially reduced.

The mechanism is growth hormone-mediated lipolysis. Increased GH secretion drives breakdown of visceral fat, which is particularly GH-responsive. The clinical effect is most pronounced in patients with elevated baseline visceral adiposity. Patients with primarily subcutaneous adiposity see smaller relative effects.

Off-label use in non-HIV patients with central obesity has smaller controlled trial bases but consistent clinical observation. Patients with metabolic syndrome features (elevated waist circumference, insulin resistance, NAFLD) are common candidates. Provider intake covers cardiometabolic risk screening to confirm tesamorelin is the appropriate tool versus a GLP-1 (for broader weight loss) or a different protocol.

Tesamorelin for growth hormone optimization

Adult growth hormone production declines with age. Peak GH secretion occurs in adolescence and young adulthood; by age 50, GH secretion is typically 50 to 70 percent below young-adult peak. The decline is implicated in age-related changes in body composition (less lean mass, more fat mass), sleep quality, recovery from exertion, and skin texture.

Tesamorelin and other GHRH-pathway peptides are used to stimulate the body's own growth hormone release back toward younger-adult levels. The advantage over recombinant HGH is preserved feedback regulation: the body's own controls remain intact, reducing the risk of supraphysiological GH excess. Tesamorelin specifically has the advantage of the longest half-life among the GHRH analogs, supporting once-daily dosing versus the multiple daily injections required by shorter-acting options.

The tesamorelin and ipamorelin blend

The tesamorelin and ipamorelin combination is one of the most popular dual-pathway growth hormone stacks. The two peptides activate different receptors to produce a stronger and cleaner GH pulse than either alone.

Tesamorelin binds GHRH receptors on the anterior pituitary, telling the gland to release more growth hormone. Ipamorelin is a selective ghrelin receptor agonist that binds a different receptor and tells the gland to release more growth hormone via a parallel pathway. The two signals are additive at the pituitary, producing a larger total GH pulse than either peptide produces alone at the same dose.

Ipamorelin is also selective for the ghrelin receptor without significant cortisol or prolactin effect, which is a notable advantage over older ghrelin agonists. The selectivity makes the tesamorelin/ipamorelin stack cleaner than alternative combinations.

RxPepsDirect prescribes the combination as Tesamorelin/Ipamorelin at 12mg tesamorelin + 6mg ipamorelin per vial, $120 per vial, covering approximately 4 to 6 weeks at typical dosing. The combination is a common choice for patients targeting body composition who want the dual-pathway advantage in one injection.

Tesamorelin vs sermorelin vs CJC-1295

Patients researching growth hormone peptides typically encounter all three molecules. Each has its place; the choice depends on goal and budget.

For deeper comparison see tesamorelin vs sermorelin.

Realistic dosing protocol

The FDA-approved Egrifta dose for HIV lipodystrophy is 2mg subcutaneous injection daily. Off-label visceral fat reduction and GH optimization protocols typically use 1mg to 2mg daily. From the 15mg multi-dose vial that translates to approximately 0.1mL to 0.2mL per injection (concentration is 3mg/mL when reconstituted to standard volume).

Some protocols use 5-day-on / 2-day-off cycling to maintain pituitary GHRH receptor responsiveness over extended cycles. Other protocols use straight daily dosing for 12 to 24 weeks followed by a 4 to 8 week washout. Provider sets the specific schedule based on indication, body weight, and prior protocol history.

Injections are subcutaneous, typically into abdominal fat in the morning. Rotating injection sites minimizes local reactions. Most patients perform injections themselves with insulin syringes; the technique is the same pinch-and-stick used for daily insulin dosing.

Side effects and safety

• Common: injection site reactions. Mild redness, swelling, or itching at injection site. Resolves within hours. Rotating sites reduces frequency.
• Common: muscle and joint aches in first 1 to 2 weeks. Mild aches as growth hormone levels rise. Usually adapts.
• Moderate: transient hyperglycemia. Growth hormone modestly raises blood sugar; insulin sensitivity may decline slightly. Patients with prediabetes or type 2 diabetes need provider monitoring of glucose.
• Moderate: mild edema or fluid retention. Occasional in the first few weeks. Usually resolves.
• Rare: carpal tunnel symptoms. Reported at higher doses or in patients with predisposing factors. Provider monitors.

Contraindications: active malignancy (GH may support tumor growth), pregnancy and breastfeeding, severe untreated sleep apnea (GH may worsen), uncontrolled type 2 diabetes, type 1 diabetes (relative). Provider screens during intake.

Cost comparison

Research-grade tesamorelin is sold by online vendors labeled "for research use only" or "not for human consumption." The molecule is often similar but the source, sterility, identity verification, and provider supervision are not. For the regulatory and quality comparison see compounded peptides vs research peptides.

How to buy tesamorelin from RxPepsDirect

1. Browse the muscle growth category and add tesamorelin to your protocol. Choose between:
   • Tesamorelin 15mg ($100): standard daily dosing for most protocols.
   • Tesamorelin High-Dose 24mg ($200): higher per-injection dose or extended cycle protocols.
   • Tesamorelin/Ipamorelin 12mg+6mg ($120): dual-pathway GH stack.
2. Pay the $39 medical visit fee at checkout and complete the clinical intake. Disclose current medications, recent labs, and goals.
3. A licensed clinician in your state reviews the intake. Dr. Jonathan Snipes, MD (Medical Director, NPI 1821250077) oversees clinical protocols. Kim Callender, NP signs the prescription after individual review.
4. Optimal Balance Pharmacy compounds the vial, runs per-batch sterility and endotoxin testing, and texts a secure payment link for the medication at wholesale.
5. The vial ships pre-reconstituted via FedEx Overnight in a reusable cooled travel case. Insulin syringes, alcohol swabs, and the prescriber's written dosing protocol are included.

Ready to start

For cash-pay patients targeting visceral fat reduction, growth hormone optimization, or body composition goals, compounded tesamorelin delivers the same active molecule as branded Egrifta at a fraction of the cost. Browse Tesamorelin 15mg for the standard daily protocol, or the Tesamorelin/Ipamorelin blend for the dual-pathway stack. For broader peptide category context see the peptide therapy overview.